Session » SLE – Treatment Poster (1732–1772)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1768

Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity

8:30AM-10:30AM: Abstract Number: 1759

An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients

8:30AM-10:30AM: Abstract Number: 1741

Anifrolumab Results in Favorable Responses Regardless of SLE Disease Duration: Post Hoc Analysis of Data from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1772

Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial

8:30AM-10:30AM: Abstract Number: 1746

Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial

8:30AM-10:30AM: Abstract Number: 1763

Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1747

BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

8:30AM-10:30AM: Abstract Number: 1769

BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects

8:30AM-10:30AM: Abstract Number: 1756

Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients

8:30AM-10:30AM: Abstract Number: 1733

Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria

8:30AM-10:30AM: Abstract Number: 1757

Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series

8:30AM-10:30AM: Abstract Number: 1761

Comparison of Belimumab and Standard of Care by Inverse Probability of Treatment Weighting Analyses Based on Propensity Score in Patients with Systemic Lupus Erythematosus in the Maintenance Phase

8:30AM-10:30AM: Abstract Number: 1767

CXCL5 Dampens Inflammation in Murine Lupus by Orchestral Suppression of Effector Cell Proliferation and Leukocyte Extravasation

8:30AM-10:30AM: Abstract Number: 1734

Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study

8:30AM-10:30AM: Abstract Number: 1754

Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1732

Effects of B Cell Activating Factors/B Lymphocyte Stimulator Inhibitors Added to Standard of Care on Infection in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

8:30AM-10:30AM: Abstract Number: 1740

Efficacy of Anifrolumab in Patients with SLE Previously Treated with Biologics: Post Hoc Analysis of Data from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1742

Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1752

Efficacy of Voclosporin in Recent Onset Lupus Nephritis

8:30AM-10:30AM: Abstract Number: 1764

Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

8:30AM-10:30AM: Abstract Number: 1771

First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8

8:30AM-10:30AM: Abstract Number: 1735

Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

8:30AM-10:30AM: Abstract Number: 1762

Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications

8:30AM-10:30AM: Abstract Number: 1753

Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors

8:30AM-10:30AM: Abstract Number: 1744

Improvement of Renal and Non-Renal SLE Outcome Measures on Sirolimus Therapy – a 21-year Follow-up Study of 73 Patients

8:30AM-10:30AM: Abstract Number: 1755

Increasing Participation of Underrepresented Groups in Lupus Clinical Trials: Insights from Qualitative Interviews with Patients and Physicians

8:30AM-10:30AM: Abstract Number: 1770

Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic

8:30AM-10:30AM: Abstract Number: 1766

Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients

8:30AM-10:30AM: Abstract Number: 1750

Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study

8:30AM-10:30AM: Abstract Number: 1760

Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus

8:30AM-10:30AM: Abstract Number: 1745

Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis

8:30AM-10:30AM: Abstract Number: 1737

Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial

8:30AM-10:30AM: Abstract Number: 1765

Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG A and/or Two BILAG B Domain Scores?

8:30AM-10:30AM: Abstract Number: 1739

SLE Treatment History and Anifrolumab Efficacy by Baseline Standard Therapies in Patients with SLE from 2 Phase 3 Trials

8:30AM-10:30AM: Abstract Number: 1748

The Peroxisome Proliferator-Activated Receptor-γ (PPAR) Agonist Pioglitazone Improves Vascular and Metabolic Dysfunction in Patients with Systemic Lupus Erythematosus (SLE)

8:30AM-10:30AM: Abstract Number: 1736

Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23

8:30AM-10:30AM: Abstract Number: 1749

Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period

8:30AM-10:30AM: Abstract Number: 1738

Uveitis Status in Patients with Ankylosing Spondylitis or Psoriatic Arthritis Under Secukinumab Treatment – Real World Data from a German Observational Study

8:30AM-10:30AM: Abstract Number: 1751

Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials

8:30AM-10:30AM: Abstract Number: 1743

Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity

8:30AM-10:30AM: Abstract Number: 1758

WITHDRAWN

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].